ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1046

Lipid Metabolic Profiling of Primary Sjögren Syndrome with Kidney Function Deficiency

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials


  • Liu, Shijia, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
  • Lu, Jiawei, China Pharmaceutical University, Nanjing, Jiangsu, China
  • Zhou, Dong, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Primary Sjögren Syndrome (pSS) is characterized by lymphocytic infiltration of the exocrine glands occurs primarily from age 50 onward, with a female to male ratio of 9:1. In the clinic, a severely affected pSS patient not only has the salivary and lacrimal glands damages, but also manifests other extraglandular diseases. Earlier research reported that lipid metabolism disorder linked to pSS caused renal disease. However, the overall lipid metabolic profile of pSS remains unknown. The aim of this study is to analyze lipid metabolic signature of the pSS patients with declined estimation of glomerular filtration rate (eGFR) by which to provide a new angle to underlying the pathogenesis of pSS associated renal diseases.


Dionex UltiMate 300 Ultra-high performance liquid chromatography system coupled online via electrospray ionization source with an Q Extractive Orbitrap MS instrument was used to evaluate lipid metabolites in 210 female patients with pSS, compared with 396 healthy subjects. We conducted analysis of covariance with potential confounders as covariates. Receiver operating characteristic (ROC) curves were plotted to explore the significance of multiple biomarkers for renal function in pSS.


We identified 1001 differentially expressed lipid metabolites between healthy adults and the pSS patients. Subtype comparisons also revealed significantly differentially expressed lipid metabolites between the pSS patients with eGFR<90ml/min/1.73m2 and eGFR>90ml/min/1.73m2. Changes in triacylglycerol (50:4/14:0-18:2) and Phosphatidyl cholines (40:8/20:4) were the most distinctive lipids between the pSS patients eGFR<90ml/min/1.73m2 and eGFR>90ml/min/1.73m2. Particularly, the diagnostic outcomes are shown via the ROC curves for comparison between healthy adults vs pSS (eGFR>90ml/min/1.73m2), healthy adults vs pSS (eGFR<90ml/min/1.73m2), and pSS patients eGFR>90ml/min/1.73m2 vs eGFR<90ml/min/1.73m2. Consistent with the eGFR levels, specific lipidomics-based biomarkers provided AUC of 0.975 to 0.986 in different stage of kidney disease, compared with the healthy controls. The AUC is 0.690 if directly compare the pSS patients with eGFR>90ml/min/1.73m2 or eGFR<90ml/min/1.73m2.


pSS patients are characterized by a distinct lipid metabolic profile providing new insights into the pathogenesis of pSS renal damages.